EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction

NCT ID: NCT01323829

Last Updated: 2014-05-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-11-30
• Study Completion Date: 2013-12-31

Brief Summary

This is a prospective, pilot, longitudinal study to evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD. The objective of this study is to determine the efficacy of injecting botulinum toxin type A into pelvic floor muscles that are high tone. Patients who have been diagnosed with high tone pelvic floor muscle dysfunction and have failed other treatments will be eligible to participate in this study. Study related procedures will include perineometry readings. Patients will be required to complete 7 questionnaires for this study. These include visual analog scale (scale from 0-10) for pain (VAS), the O'Leary-Sant urinary symptoms and problem questionnaires (ICSI/ICPI), Pelvic Floor Distress Inventory 20 (PFDI-20), the Female Sexual Distress Scale (FSDS), Global Response Assessment Scale and the SF-12 quality of life scale. The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections. This is a prospective, pilot, longitudinal study to evaluate the effect of Botox A injection for chronic pelvic pain and HTPFD.

Conditions

High Tone Pelvic Floor Dysfunction

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

EMG Guidance of Injection

The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Participant must be diagnosed with High Tone Pelvic Floor Dysfunction(HTPMFD).
• Participant must have tried and failed at least one other conventional mode of therapy for HTPMFD.
• Participant must be a female at least 18 years of age.
• Participant must give written informed consent to participate in this study.
• Participant must be able to make decisions for herself.
• Participant must not be undergoing another procedure at the time of BTX A injection.

Exclusion Criteria

• Participant is male.
• Patient has a history of past BTX A use
• Patient has had pelvic organ prolapse repair
• Participant is pregnant or intends to get pregnant during the study period or is breastfeeding.
• Participant is unwilling or unable (because of long distance from office) to follow-up.
• Participant has a neuro-modulator device implanted.
• Participant has a known bleeding disorder or is on anticoagulation.
• Participant has a known hypersensitivity to BTX A.
• Participant has a pre-existing neuromuscular disorder such as amytrophic lateral sclerosis, motor neuropathy, myasthenia gravis or Lambert-Eaton syndrome.
• Participant with skin infection at the perineum at the site of injection.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Allergan

INDUSTRY

Sponsor Role: collaborator

Pelvic and Sexual Health Institute

OTHER

Sponsor Role: lead

Responsible Party

Kristene Whitmore, M.D.

Medical Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kristene E Whitmore, MD

Role: PRINCIPAL_INVESTIGATOR

Pelvic and Sexual Health Institute

Locations

Pelvic and Sexual Health Institute

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

BTXA EMG

Identifier Type: -

Identifier Source: org_study_id